NCT06802016 is a clinical trial in Bicuspid Aortic Valve (BAV), sponsored by Ruijin Hospital.

Who is sponsoring NCT06802016?

NCT06802016 is sponsored by Ruijin Hospital.

What condition does NCT06802016 study?

NCT06802016 studies Bicuspid Aortic Valve (BAV).

Is NCT06802016 still recruiting?

NCT06802016 is currently recruiting now. Last updated 3 February 2025.

Last reviewed 2025-02-03 · How we verify

NCT06802016

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Chinese Congenital Bicuspid Aortic Valve

Recruiting now Last updated 3 February 2025

What this trial tests

trial in Bicuspid Aortic Valve (BAV) in 500 participants. Currently enrolling.

Timeline

18 January 2025

Primary endpoint
31 December 2029

31 December 2035

Quick facts

Lead sponsor	Ruijin Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	500
Start date	18 January 2025
Primary completion	31 December 2029
Estimated completion	31 December 2035
Sites	1 location across China

Conditions studied

Bicuspid Aortic Valve (BAV) — all drugs for Bicuspid Aortic Valve (BAV) →

Sponsor

Ruijin Hospital

Who can join

Adults 14 to 60, any sex, with Bicuspid Aortic Valve (BAV). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pervious studies indicated that the prevalence of bicuspid aortic valve（BAV） might be higher in China. There is a familial predisposition to the development of BAV. The study analyzed epidemiological data on selected BAV and established a BAV cohort to observe disease progression and treatment outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Bicuspid Aortic Valve (BAV)

Currently open trials in the same condition.

NCT06830499 — Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China · recruiting
NCT06657911 — Size Up Bicuspid With the LIra MEthod: the SUBLIME Study · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06802016 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 3 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06802016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing